Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone

Annals of Oncology

Volumn 19, Issue 12, 2008, Pages 2048-2052

  Goel, Sanjay ^a,b   Goldberg, G L ^a,b   Kuo, D Y S ^a,b   Muggia, F ^c   Arezzo, J ^a   Mani, S ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Ixabepilone; Nerve conduction test (NCT); Phase I; Solid tumors; Vibration perception threshold (VPT)

Indexed keywords

DOCETAXEL; IXABEPILONE; IXEMPRA; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOATING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORRELATION ANALYSIS; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG FEVER; FATIGUE; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GYNECOLOGIC CANCER; HUMAN; INFECTION; INSOMNIA; KIDNEY FUNCTION; LATENT PERIOD; LEG EDEMA; LIVER FUNCTION TEST; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MONOTHERAPY; MOTOR NEUROPATHY; MOTOR PERFORMANCE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NEUTROPENIA; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; VIBRATION SENSE; VOMITING; WEIGHT REDUCTION;

EID: 56849084181     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn420     Document Type: Article

References (28)

1. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-5217.
2. Roché H, Yelle L, Cognetti G et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25: 3415-3420.
3. Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21: 1866-1873.
4. Vansteenkiste J, Lara PN Jr, Le Chevalier T et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007; 25: 3448-3455.
5. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25: 3407-3414.
6. Lee JJ, Low JA, Croarkin E et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 2006; 24: 2084-2091.
7. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24: 1633-1642.
8. http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf (14 April 2008, date last accessed).
9. http://www.physitemp.com/sensory.htm#vibration (14 April 2008, date last accessed).
10. http://www.neurometrix.com/products.htm (14 April 2008, date last accessed).
11. Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10: 1289-1298.
12. Hilpert F, Stahle A, Tome O et al. Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy-a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005; 13: 797-805.
13. Moore DH, Donnelly J, McGuire WP et al. Gynecologic Oncology Group. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 4207-4213.
14. Lipton RB, Galer BS, Dutcher JP et al. Large and small fibre type sensory dysfunction in patients with cancer. J Neurol Neurosurg Psychiatry 1991; 54: 706-709.
15. Hilkens PH, Pronk LC, Verweij J et al. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997; 75: 417-422.
16. Hilkens PH, Verweij J, Stoter G et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104-8.
17. Martin JH. Neuroanatomy: Text and Atlas. Appleton and Lange. 3rd edition. Norwalk, CT 2003; 108-112.
18. Duke J, McEvoy M, Sibbritt D et al. Vibrotactile threshold measurement for detecting peripheral neuropathy: Defining variability and a normal range for clinical and research use. Diabetologia 2007; 50: 2305-2312.
19. Jurado J, Ybarra J, Pou JM. Isolated use of vibration perception thresholds and semmes-weinstein monofilament in diagnosing diabetic polyneuropathy: ''the North Catalonia diabetes study. Nurs Clin North Am 2007; 42: 59-66.
20. Coppini DV, Wellmer A, Weng C et al. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. J Clin Neurosci 2001; 8: 520-524.
21. Hilkens PH, van der Burg ME, Moll JW et al. Effect of an ACTH (4-9) analogue on cisplatin neuropathy of longstanding duration: A phase II study. Clin Neurol Neurosurg 1995; 97: 139-141.
22. van den Bent MJ, van Putten WL, Hilkens PH et al. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur J Cancer 2002; 38: 387-391.
23. Mielke S, Sparreboom A, Steinberg SM et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005; 11: 4843-4850.
24. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-190.
25. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25: 3399-3406.
26. Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25: 3421-3427.
27. Gao WQ, Dybdal N, Shinsky N et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995; 38: 30-37.
28. Albers J, Chaudhry V, Cavaletti G, Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2007; (1): CD005228.